Project Update – May 2026

Project Update – May 28, 2026

We are delighted to report that Zivo Bioscience has entered into a strategic collaboration with a highly regarded global animal health company to advance our novel immune-modulating compounds for use across multiple poultry market segments. This collaboration includes an exclusive evaluation period related to poultry applications, and may expand over time to address additional unmet needs in livestock and companion animals.

Under the agreement, our collaborator will conduct a coccidiosis challenge study that is designed to determine the minimum effective dose of our proprietary biological candidate under commercially relevant conditions. The study is expected to support regulatory advancement and further assess the product’s commercial potential.

ZIVO’s business strategy features cost-effective partnerships such as this one to optimize the commercial positioning and opportunity of our products at global scale. Our two companies share the promise of our immune-modulating technology to create a disruptive, non-antibiotic therapeutic platform, and we look forward to the outcomes of this collaboration.